Conditions: Major Depressive Disorder
Keywords: Major Depressive Disorder MDD Depression
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 363
Healthy volunteers: no

Brief summary:
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Desvenlafaxine Succinate Sustained-Release intervention 2: Desvenlafaxine Succinate Sustained-Release intervention 3: Placebo
Intervention descriptions: intervention 1: Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit. intervention 2: Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit. intervention 3: Subjects randomized to the Placebo treatment arm will receive placebo tablets

Protocol document: